{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:49:07Z","timestamp":1787064547964,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.2215\/cjn.02480314","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T00:24:21Z","timestamp":1397175861000},"page":"831-836","source":"Crossref","is-referenced-by-count":11,"title":["Novel Treatments of Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"9","author":[{"given":"Rex L.","family":"Mahnensmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20230601","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R2-1-20230601","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-1-20230601","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ackd.2010.01.006","article-title":"Treatment strategies and clinical trial design in ADPKD","volume":"17","author":"Torres","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"R4-1-20230601","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R5-1-20230601","first-page":"252","article-title":"Molecular genetics of autosomal dominant polycystic kidney disease","volume":"26","author":"Pei","year":"2003","journal-title":"Clin Invest Med"},{"key":"R6-1-20230601","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s10157-012-0611-9","article-title":"Renal disease progression in autosomal dominant polycystic kidney disease","volume":"16","author":"Higashihara","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"R7-1-20230601","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"R8-1-20230601","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"R9-1-20230601","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R10-1-20230601","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R11-1-20230601","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R12-1-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.2007101100","article-title":"Therapy for polycystic kidney disease? It\u2019s water, stupid!","volume":"19","author":"Grantham","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R13-1-20230601","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R14-1-20230601","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-1-20230601","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2009.438","article-title":"Cyclic nucleotide signaling in polycystic kidney disease","volume":"77","author":"Wang","year":"2010","journal-title":"Kidney Int"},{"key":"R16-1-20230601","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","article-title":"Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease","volume":"22","author":"Devuyst","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R17-1-20230601","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R18-1-20230601","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"R19-1-20230601","first-page":"8","article-title":"Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats","volume":"7","author":"Winkler","year":"1982","journal-title":"Miner Electrolyte Metab"},{"key":"R20-1-20230601","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1681\/ASN.V271219","article-title":"Cyst decompression surgery for autosomal dominant polycystic kidney disease","volume":"2","author":"Elzinga","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"R21-1-20230601","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N Engl J Med"},{"key":"R22-1-20230601","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1573402111309010003","article-title":"Renin-angiotensin-aldosterone system in autosomal dominant polycystic kidney disease","volume":"9","author":"Tkachenko","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"R23-1-20230601","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","article-title":"Hypertension in autosomal dominant polycystic kidney disease","volume":"17","author":"Chapman","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"R24-1-20230601","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1681\/ASN.2008080882","article-title":"Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease","volume":"20","author":"Schrier","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R25-1-20230601","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.02810608","article-title":"Prospective change in renal volume and function in children with ADPKD","volume":"4","author":"Cadnapaphornchai","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-1-20230601","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT polycystic kidney disease trials: Design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-1-20230601","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"R28-1-20230601","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R29-1-20230601","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R31-1-20230601","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","article-title":"Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease","volume":"159","author":"Erickson","year":"2013","journal-title":"Ann Intern Med"},{"key":"R32-1-20230601","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.transproceed.2009.05.032","article-title":"Sirolimus therapy for patients with adult polycystic kidney disease: A pilot study","volume":"41","author":"Soliman","year":"2009","journal-title":"Transplant Proc"},{"key":"R33-1-20230601","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R34-1-20230601","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"R35-1-20230601","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/ndt\/gfs264","article-title":"Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): A randomized, controlled study","volume":"27","author":"Stallone","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R36-1-20230601","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: An open-label randomized control pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"R37-1-20230601","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"R38-1-20230601","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJMc1010845","article-title":"mTOR inhibitors and autosomal dominant polycystic kidney disease","volume":"364","author":"Granthum","year":"2011","journal-title":"N Engl J Med"},{"key":"R39-1-20230601","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"R40-1-20230601","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R41-1-20230601","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"R42-1-20230601","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"R43-1-20230601","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201405000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:19Z","timestamp":1786369459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201405000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02480314","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}